Xinfeng Yang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18.
Journal: Nature communications
Published: November 14, 2024
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.
Journal: Signal transduction and targeted therapy
Published: June 05, 2024
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial.
Journal: Med (New York, N.Y.)
Published: May 17, 2024
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study.
Journal: Innovation (Cambridge (Mass.))
Published: March 09, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Journal: Journal for immunotherapy of cancer
Published: January 29, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Journal: Cancer immunology, immunotherapy : CII
Published: September 13, 2023
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 27, 2022
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.
Journal: Translational lung cancer research
Published: January 10, 2022
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
Journal: BMC medicine
Published: November 15, 2021
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Journal: Annals of translational medicine
Published: September 10, 2021
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 09, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026